{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:56:49Z","timestamp":1794337009512,"version":"4.9.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T00:00:00Z","timestamp":1552435200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81572963"],"award-info":[{"award-number":["No. 81572963"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13014-019-1240-1","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T09:04:11Z","timestamp":1552467851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses"],"prefix":"10.1186","volume":"14","author":[{"given":"Jianjiao","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yida","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqing","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,13]]},"reference":[{"key":"1240_CR1","doi-asserted-by":"crossref","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2018;68(6):394\u2013424.","DOI":"10.3322\/caac.21492"},{"key":"1240_CR2","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1093\/annonc\/mds124","volume":"23","author":"M Takeda","year":"2012","unstructured":"Takeda M, Okamoto I, Sakai K, Kawakami H, Nishio K, Nakagawa K. Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Ann Oncol. 2012;23:2931\u20136.","journal-title":"Ann Oncol"},{"key":"1240_CR3","doi-asserted-by":"publisher","first-page":"7268","DOI":"10.1038\/srep07268","volume":"4","author":"S Hong","year":"2014","unstructured":"Hong S, Fang W, Hu Z, et al. A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population. Sci Rep. 2014;4:7268.","journal-title":"Sci Rep"},{"key":"1240_CR4","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693\u2013703.","journal-title":"N Engl J Med"},{"key":"1240_CR5","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167\u201377.","journal-title":"N Engl J Med"},{"key":"1240_CR6","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385\u201394.","journal-title":"N Engl J Med"},{"key":"1240_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.semcdb.2016.09.016","volume":"64","author":"M Qian","year":"2017","unstructured":"Qian M, Zhu B, Wang X, Liebman M. Drug resistance in ALK-positiveNon-small cell lungcancer patients. Semin Cell Dev Biol. 2017;64:150\u20137.","journal-title":"Semin Cell Dev Biol"},{"issue":"Suppl 3","key":"1240_CR8","doi-asserted-by":"publisher","first-page":"iii42","DOI":"10.1093\/annonc\/mdw305","volume":"27","author":"I Dagogo-Jack","year":"2016","unstructured":"Dagogo-Jack I, Shaw AT. Crizotinib resistance: implications for therapeutic strategies. Ann Oncol. 2016;27(Suppl 3):iii42\u201350.","journal-title":"Ann Oncol"},{"key":"1240_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1200\/JCO.2015.62.0138","volume":"34","author":"KL Johung","year":"2016","unstructured":"Johung KL, Yeh N, Desai NB, et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung Cancer and brain metastasis. J Clin Oncol. 2016;34:123\u20139.","journal-title":"J Clin Oncol"},{"key":"1240_CR10","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","volume":"33","author":"DB Costa","year":"2015","unstructured":"Costa DB, Shaw AT, Ou SH, et al. Clinical experience with Crizotinib in patients with advanced ALK-rearranged non-small-cell lung Cancer and brain metastases. J Clin Oncol. 2015;33:1881\u20138.","journal-title":"J Clin Oncol"},{"key":"1240_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.radonc.2014.12.009","volume":"114","author":"Y Dai","year":"2015","unstructured":"Dai Y, Wei Q, Schwager C, et al. Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer. Radiother Oncol. 2015;114:173\u201381.","journal-title":"Radiother Oncol"},{"key":"1240_CR12","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1158\/1535-7163.MCT-12-0868","volume":"12","author":"Y Sun","year":"2013","unstructured":"Sun Y, Nowak KA, Zaorsky NG, et al. ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK. Mol Cancer Ther. 2013;12:696\u2013704.","journal-title":"Mol Cancer Ther"},{"key":"1240_CR13","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.ijrobp.2013.11.010","volume":"88","author":"GN Gan","year":"2014","unstructured":"Gan GN, Weickhardt AJ, Scheier B, et al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys. 2014;88:892\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1240_CR14","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.jtho.2017.12.006","volume":"13","author":"TP Robin","year":"2018","unstructured":"Robin TP, Camidge DR, Stuhr K, et al. Excellent outcomes with radiosurgery for multiple brain metastases in ALK and EGFR driven non-small cell lung Cancer. J Thorac Oncol. 2018;13:715\u201320.","journal-title":"J Thorac Oncol"},{"key":"1240_CR15","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Non-small cell lung cancer. Version 2.2019-November 21,2018. \n                    https:\/\/www.nccn.org\/professionals\n                    \n                  . Accessed 28 Jan 2019."},{"key":"1240_CR16","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1016\/j.prro.2016.05.004","volume":"6","author":"HA Al-Hallaq","year":"2016","unstructured":"Al-Hallaq HA, Chmura S, Salama JK, et al. Rationale of technical requirements for NRG-BR001: the first NCI-sponsored trial of SBRT for the treatment of multiple metastases. Practical Radiat Oncol. 2016;6:e291\u20138.","journal-title":"Practical Radiat Oncol"},{"key":"1240_CR17","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1097\/JTO.0000000000000648","volume":"10","author":"H Al-Halabi","year":"2015","unstructured":"Al-Halabi H, Sayegh K, Digamurthy SR, et al. Pattern of failure analysis in metastatic EGFR-mutant lung Cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy. J Thorac Oncol. 2015;10:1601\u20137.","journal-title":"J Thorac Oncol"},{"key":"1240_CR18","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1080\/02841860802662722","volume":"48","author":"KE Rusthoven","year":"2009","unstructured":"Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares M, Camidge DR. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol. 2009;48:578\u201383.","journal-title":"Acta Oncol"},{"key":"1240_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3111\/13696998.2014.1003644","volume":"18","author":"A Guerin","year":"2015","unstructured":"Guerin A, Sasane M, Zhang J, et al. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. J Med Econ. 2015;18:312\u201322.","journal-title":"J Med Econ"},{"key":"1240_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","volume":"316","author":"PD Brown","year":"2016","unstructured":"Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. Jama. 2016;316:401\u20139.","journal-title":"Jama"},{"key":"1240_CR21","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMct0806951","volume":"362","author":"JH Suh","year":"2010","unstructured":"Suh JH. Stereotactic radiosurgery for the management of brain metastases. N Engl J Med. 2010;362:1119\u201327.","journal-title":"N Engl J Med"},{"key":"1240_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3389\/fonc.2018.00154","volume":"8","author":"D Hartgerink","year":"2018","unstructured":"Hartgerink D, van der Heijden B, De Ruysscher D, et al. Stereotactic radiosurgery in the Management of Patients with Brain Metastases of non-small cell lung Cancer: indications, decision tools and future directions. Front Oncol. 2018;8:154.","journal-title":"Front Oncol"},{"key":"1240_CR23","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.ijrobp.2014.12.010","volume":"91","author":"E Topkan","year":"2015","unstructured":"Topkan E, Yildirim BA, Guler OC, Parlak C, Pehlivan B, Selek U. Safety and palliative efficacy of single-dose 8-Gy reirradiation for painful local failure in patients with stage IV non-small cell lung cancer previously treated with radical chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2015;91:774\u201380.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1240_CR24","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1200\/JCO.2007.15.3312","volume":"26","author":"A Fairchild","year":"2008","unstructured":"Fairchild A, Harris K, Barnes E, et al. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol. 2008;26:4001\u201311.","journal-title":"J Clin Oncol"},{"key":"1240_CR25","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","volume":"7","author":"AJ Weickhardt","year":"2012","unstructured":"Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7:1807\u201314.","journal-title":"J Thorac Oncol"},{"key":"1240_CR26","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","volume":"389","author":"JC Soria","year":"2017","unstructured":"Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389:917\u201329.","journal-title":"Lancet"},{"key":"1240_CR27","doi-asserted-by":"crossref","unstructured":"Gadgeel S, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol: official journal of the European Society for Medical Oncology. 2018;29(11):2214\u201322.","DOI":"10.1093\/annonc\/mdy405"},{"key":"1240_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/bjc.2017.395","volume":"118","author":"S Gadgeel","year":"2018","unstructured":"Gadgeel S, Shaw AT, Barlesi F, et al. Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. Br J Cancer. 2018;118:38\u201342.","journal-title":"Br J Cancer"},{"key":"1240_CR29","doi-asserted-by":"crossref","unstructured":"Camidge DR, Kim DW, Tiseo M, et al. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. J Clin Oncol: official journal of the American Society of Clinical Oncology. 2018;36(26):2693\u20132701.","DOI":"10.1200\/JCO.2017.77.5841"},{"key":"1240_CR30","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/annonc\/mdt572","volume":"25","author":"SH Ou","year":"2014","unstructured":"Ou SH, Janne PA, Bartlett CH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol. 2014;25:415\u201322.","journal-title":"Ann Oncol"},{"key":"1240_CR31","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.7150\/jca.24950","volume":"9","author":"J Liu","year":"2018","unstructured":"Liu J, Cui S, Pan F, et al. Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with ALK\/ROS-1 mutations. J Cancer. 2018;9:1863\u20139.","journal-title":"J Cancer"},{"key":"1240_CR32","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw AT, Kim TM, Crino L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18:874\u201386.","journal-title":"Lancet Oncol"},{"key":"1240_CR33","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","volume":"29","author":"S Novello","year":"2018","unstructured":"Novello S, Mazieres J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29:1409\u201316.","journal-title":"Ann Oncol"},{"key":"1240_CR34","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","volume":"35","author":"DW Kim","year":"2017","unstructured":"Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in patients with Crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung Cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35:2490\u20138.","journal-title":"J Clin Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-019-1240-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-019-1240-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-019-1240-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T20:17:44Z","timestamp":1583957864000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-019-1240-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,13]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1240"],"URL":"https:\/\/doi.org\/10.1186\/s13014-019-1240-1","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,13]]},"assertion":[{"value":"19 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the institutional review board of Fudan University Shanghai Cancer Center.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"44"}}